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Abstract
Background: Patients with chronic lymphocytic leukemia and 13q deletion as their only FISH abnormality could have a
different outcome depending on the number of cells displaying this aberration. Thus, cases with a high number of 13q- cells
(13q-H) had both shorter overall survival and time to first therapy. The goal of the study was to analyze the genetic profile of
13q-H patients.
Design and Methods:: A total of 102 samples were studied, 32 of which served as a validation cohort and five were healthy
donors.
Results: Chronic lymphocytic leukemia patients with higher percentages of 13q- cells (.80%) showed a different level of
gene expression as compared to patients with lower percentages (,80%, 13q-L). This deregulation affected genes involved
in apoptosis and proliferation (BCR and NFkB signaling), leading to increased proliferation and decreased apoptosis in 13q-H
patients. Deregulation of several microRNAs, such as miR-15a, miR-155, miR-29a and miR-223, was also observed in these
patients. In addition, our study also suggests that the gene expression pattern of 13q-H cases could be similar to the
patients with 11q- or 17p-.
Conclusions: This study provides new evidence regarding the heterogeneity of 13q deletion in chronic lymphocytic
leukemia patients, showing that apoptosis, proliferation as well as miRNA regulation are involved in cases with higher
percentages of 13q- cells.
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Introduction
Chronic lymphocytic leukemia (CLL) is characterized by the
progressive accumulation of mature, monoclonal B lymphocytes in
the blood, bone marrow (BM) and secondary lymphoid tissues [1].
The clinical course ranges from an indolent disorder with a
normal lifespan to a rapidly progressive disease leading to death
[2,3]. The variable clinical course of CLL is driven, at least in part,
by the immunogenetic and molecular heterogeneity of the disease
[4,5]. The genomic aberrations and the immunoglobulin (Ig) VH
mutation status provide us with two separate genetic parameters of
prognostic relevance. Thus, patients whose leukemic cells express
unmutated IgVH regions (Ig-unmutated CLL) often have progres-
sive disease, whereas those whose leukemic cells express mutated
IgVH regions (Ig-mutated CLL) more often have an indolent
disease [4,6]. Fluorescent in situ hybridization (FISH) can detect
genomic abnormalities in more than 80% of CLL cases and the
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genetic subtypes of CLL show different biological and clinical
features [5]. Although unfavorable aberrations (losses on 17p and
11q) are more frequent in the Ig-unmutated subgroup [7–9], and
favorable aberrations (loss on 13q as a single abnormality) are
more frequent in the Ig-mutated subgroup, they have independent
value in predicting outcome in CLL [8,9].
Deletion at 13q14 (13q-) is the most common genomic
aberration in CLL. It is present in more than 50% of cases, and
is the sole documented cytogenetic abnormality in 36% of the
patients. These latter cases are known to have a more favorable
clinical course [5,10]. However, recent data from our group and
others, suggest that patients with CLL and 13q deletion as the only
FISH abnormality could have a different outcome depending on
the number of cells displaying this aberration [11–13]. Moreover,
previous studies had demonstrated that the percentage of cells
displaying a particular cytogenetic abnormality (e.g. loss of P53)
[14] or antigenic markers (e.g. CD38 or ZAP-70) [7] can be
related to prognosis. We have demonstrated that cases with a high
number of 13q- cells (13q-H) usually had both shorter overall
survival and time to first therapy. However, to the best of our
knowledge the molecular characteristics of 13-H CLLs have not
been so far analyzed in detail in order to better understand why
these patients have a poor outcome.
The value of gene expression profiling (GEP) in the study of
CLL is widely accepted. Such studies have identified new
prognosis markers such as ZAP-70, LPL, PEG10 and CLLU1.
Some of these are already well-established factors used in clinical
practice, while the application of others is under study.
As a next step toward elucidation of biological differences within
13q- subgroup, the current study used the Affymetrix Human
Exon arrays 1.0 ST, which offer a more fine-grained view of gene
expression than the former generation of chips. Thus, the data
obtained provide great insights into the biological mechanisms
underlying the clinical differences observed in this CLL subgroup
[11–13].
Materials and Methods
Patients
A total of 102 samples were selected for the study, 32 of which
served as a validation cohort and five were healthy donors. CLL
diagnosis was performed according to the World Health Organi-
zation (WHO) classification [15] and the Working Group of
National Cancer Institute (NCI) criteria [16]. A complete
immunophenotypic analysis by flow cytometry [17] and FISH
studies were carried out in all cases. The median age at the time of
study was 68 years (range, 35 to 90 years). Most patients were male
(66%) and were in Binet clinical stage A (69%), while 26% were in
stage B, and the remaining 5% were in stage C. The clinical and
biological features of the CLL patients included in the study are
shown in Table S1. The study was approved by the local ethical
committees ‘‘Comite´ E´tico de Investigacio´n Clı´nica, Hospital
Universitario de Salamanca’’. Written informed consent was
obtained from each patient before they entered the study.
Methods
B cell isolation. Peripheral blood mononuclear cells
(PBMCs) were isolated from fresh peripheral blood samples using
Ficoll gradient, snap-frozen and stored at –80uC.
For the validation cohort, CD19-positive B cells were purified
by magnetically activated cell sorting (MACS) CD19 MicroBeads
(Miltenyi Biotec, Bergisch Gladbach, Germany) resulting in a
.98% purity, as analyzed by flow cytometry. CD19-positive
normal B cells from peripheral blood of five healthy donors served
as controls.
Genomic aberrations. For the purpose of the study, only
samples with one cytogenetic abnormality were included. For the
gene expression profile analysis, according to our previous results
[11], two groups of patients with 13q- were compared: those in
whom 80% or more of cells showed 13q- (13q-H) and those in
whom fewer than 80% of cells showed 13q losses (13q-L). The
distribution of cases in the study cohort was: 13q-H (n = 25; 36%),
13q-L (n = 27; 39%), normal FISH (nCLL, n = 8; 11%) and
17p2/11q- (n = 10; 14%).
In the validation cohort, the distribution of samples was similar:
13q-H (n = 7; 22%), 13q-L (n = 11; 34%) and nCLL (n = 9; 28%).
The remaining five cases were healthy donors.
Mutation status of IGVH genes. IGVH genes were
amplified and sequenced according to the ERIC recommenda-
tions on IGHV gene mutational status analysis in CLL [18].
Global gene expression using high density
microarrays. Genome-wide expression analysis of the isolated
samples was performed using Human Exon 1.0 ST microarrays
(Affymetrix). RNA isolation, labeling and microarray hybridiza-
tion were carried out following the manufacturer’s protocols for
the GeneChip platform by Affymetrix. Methods included synthesis
of first- and second-strand cDNAs, the purification of double-
stranded cDNA, synthesis of cRNA by in vitro transcription,
recovery and quantization of biotin-labeled cRNA, fragmentation
of this cRNA and subsequent hybridization to the microarray
slide, post-hybridization washings, and detection of the hybridized
cRNAs using a streptavidin-coupled fluorescent dye. Hybridized
Affymetrix arrays were scanned with an Affymetrix Gene-Chip 3000
scanner. Images were generated and features extracted using
Affymetrix GCOS Software.
Table 1. miRNAs significantly deregulated between 13q- CLL
subgroups (patients with 80% or more of cells with 13q
deletion and patients with less than 80% 13q cells).
miRNA Map q-value R fold
Down-regulated
hsa-mir-1-1* 20q13.33 0.0125 0.7027
hsa-mir-7-1 9q21.32 0.0397 0.5453
hsa-mir-15a 13q14.3 0.0329 0.4917
hsa-mir-29a 7q32.3 0.0354 0.5101
hsa-mir-34a* 1p36.23 0.0366 0.6874
hsa-mir-106b* 7q22.1 0.0280 0.5190
hsa-mir-181b 1q31.3 0.0256 0.6775
hsa-mir-204 9q21.11 0.0294 0.5693
hsa-mir-206 6p12.2 0.0476 0.7077
hsa-mir-221* Xp11.3 0.0133 0.4622
hsa-mir-223* Xq12 0.0017 0.1016
Up-regulated
hsa-mir-134 14q32.31 0.0095 1.8096
hsa-mir-105-2 Xq28 0.0182 1.4040
hsa-mir-155* 21q21.3 0.0046 3.7013
hsa-mir-205 1q32.2 0.0161 1.3830
Upregulation or downregulation refers to 13q-H relative to13q-L CLL patients.
miRNA: microRNA.
*deregulation shared with 17p/11q CLL patients.
doi:10.1371/journal.pone.0048485.t001
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Bioinformatic analysis: normalization, signal calculation,
significant differential expression, and sample/gene profile
clustering. The Robust Microarray Analysis (RMA) algorithm
was used for background correction, intra- and inter-microarray
normalization, and expression signal calculation [19]. The
absolute expression signal for each gene was calculated for each
microarray. For the expression signal calculation of the Human
Exon arrays we used a new CDF package, called GeneMapper
(from GATExplorer) [20], instead of the Affymetrix original probe-
set definition. This mapping represents an improvement thanks to
the reannotation of updated Ensembl gene loci and removal of
cross-hybridization noise [20]. It also allows operations to be
carried out from the outset using gene identifications (Ensembl
IDs) instead of probe-sets (Affymetrix IDs). Mapping to genome
version Ensembl v53 (assembly NCBI36) was done for these
analyses.
Significance Analysis of Microarray (SAM) [21] was used to
calculate significant differential expression and to identify the gene
probe sets that characterize the samples of each compared state. In
this method, permutations provide robust statistical inference of
the most significant genes and, by using a false discovery rate
(FDR) [22], adjust the raw p-values to take multiple testing into
account. An FDR cut-off of ,0.05 was used for all the differential
expression calculations.
Finally, the Global Test [23] algorithm was used to test the
resulting lists of candidate genes associated with 13q-H subgroup.
The Global Test allows us to identify the genes that have the
global expression pattern most significantly related to the clinical
feature studied.
All the bioinformatic analyses were performed with the
statistical program R, using the custom packages Bioconductor
[24] and GATExplorer [20].
Principal component analysis. To explore and represent
the differences among the different categories studied (13q-
HCLLs, 13q-L CLLs, nCLLs and healthy controls), we applied
Principal Component Analysis (PCA) to the expression data sets,
using the normalized gene expression matrices of all samples of the
validation cohort as the input. The expression matrices were
filtered beforehand removing 25% of the least variable genes to
avoid noise produced by non-expressed genes (i.e. the remaining
28 806 genes). For each of these genes, the median expression
value across samples within each category was calculated. Next,
the following formula was designed to calculate the expression
values per gene and sample considering their variability within
each category:
Yij~
Xij kð Þ{median ikð Þ
sd ikð Þzb zmedian ikð Þ ð1Þ
where Yij is the PCA input matrix, Xij is the original expression
matrix, i is the gene, j the sample, k the category and b= 2 is a
small positive constant added to the denominator to ensure that
the variance of Yij is independent of the genes [21]. This formula
represents a way of calculating the dispersion of the biological
replicates plus its median in each category. In this way, the
clustering derived from the principal components includes a small
amount of variation between individual samples, highlighting the
differences between the categories.
Functional analysis and gene annotation. The functional
assignment of the genes included in the expression signature of
CLL cytogenetic subgroups was carried out by the Database for
Annotation, Visualization and Integrated Discovery (DAVID) and
the GeneCodis program [25], which identifies concurrent
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annotations in GO and KEGG, and thereby constructs several
groups of genes of functional significance. The most significant
biological mechanisms, pathways and functional categories in the
data sets of genes selected by statistical analysis were identified
through the use of Ingenuity Pathways Analysis Sep2011
(Ingenuity Systems, Mountain View, CA, USA).
Gene-specific semi-quantitative PCR. Semi-quantitative
SYBRgreen PCR was done in triplicate with iQTM SYBRH
Green Supermix kit (BioRad) using the IQ5 Multicolor Real-Time
PCR Detection System (Bio-Rad). Expression data for selected
genes were validated in a subset of CLL patients (n = 40). Sense
and antisense primers were designed based on the probe-sets used
by Affymetrix to synthesize the GeneChip Primer sequences
(Table S2). The ABL1 gene was used as the internal control and
the quantification of relative expression [reported as arbitrary units
(a.u.)] were performed using the comparative Ct method. The data
were not normally distributed, so non-parametric tests were used.
Expression levels of the selected genes in both groups (13q-H and
13q-L) were analyzed using the Mann-Whitney U test with a two-
tailed value of P,0.05 for statistical significance. All tests were
performed using SPSS v19.0.
Quantification of miRNA expression levels. The expres-
sion of selected mature miRNAs was assayed using the Taqman
MicroRNA Assays (Applied Biosystems) specific to hsa-mir-15a,
hsa-mir-29a, hsa-mir-155 and hsa-mir-223 in 24 CLL patients
displaying 13q- according to the manufacturer’s recommenda-
tions. The Taqman MicroRNA Assays for U43 RNA (RNU43,
Applied Biosystems) was used to normalize the relative abundance
of miRNA using the 22DCt method. All experiments were
performed in duplicate. Expression levels [reported as arbitrary
units (a.u.)] of the selected miRNAs in both groups (13q-H and
13q-L) were analyzed using the Mann-Whitney U test in SPSS
v19.0. Values of P,0.05 were considered statistically significant.
Integrative analysis of miRNA and gene expression
profile. A summary of the miRNA analysis performed in the
study is shown in the Figure S1. miRNAs with significantly
different expression (FDR,0.05) between 13q-H and 13q-L were
further analyzed to identify the networks and pathway targets. For
this purpose, IPA’s microRNA Target Filter, which enables
prioritization of experimentally validated and predicted mRNA
targets from TargetScan, TarBase, miRecords and the Ingenuity
Knowledge Base was used. This tool identified the putative targets
for the input miRNAs and then developed the networks among the
targets and identified the known and most relevant biological
functions, pathways and annotations in this enriched set of target
genes. By applying the expression pairing tool, the analysis was
focused on targets exhibiting altered expression in our analysis,
finding miRNAs and their target genes with opposite or same
expression.
Results
13q-H CLLs are Characterized by a Specific Genetic
Signature and miRNA Expression
A total of 3 450 genes significantly distinguished 13q-H from
13q-L patients. These comprised 1 244 overexpressed genes and 2
Figure 1. Gene expression levels of genes significantly upregulated in 13q-H CLL patients. Box plot of the expression levels [represented
as arbitrary units (a.u.)] of six genes with significantly different expression between 13q-H and 13q-L patients, assessed by semi-quantitative PCR
analysis. Box plots show the relative upregulation of BCR (SYK, PRKCB1 and BLNK), proliferation (LEF1 and RRAS2) and antiapoptotic (BCL2) related
genes in patients with a high number of 13q- cells compared with CLL patients with lower percentages of losses in 13q. The thick line inside the box
plot indicates the median expression levels and the box shows the 25th and 75th percentiles, while the whiskers show the maximum and minimum
values. Outliers (extreme values falling out of the main distribution) are represented by open circles. Statistical significance was determined using the
Mann-Whitney U test (P,0.05).
doi:10.1371/journal.pone.0048485.g001
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206 underexpressed in the 13q-H group, defining the 13q-H
signature. The deregulated genes of the 13q-H signature were
annotated and analyzed for the presence of overrepresented
‘‘Gene Ontology categories’’ (Table S3). The most significant
overrepresented GO biological processes in 13q-H were related to
cell cycle (P,0.0001), ribosome (P,0.0001) and regulation of
transcription (P,0.0001). Moreover, 13q-H CLLs had higher
levels of expression of LEF1, BCL2, CARD11, HDAC9, NAFTC1,
NFATC2, PAX5, FCRL2 and SOS1, while we identified several
other genes downregulated in 13q-H, such as GAS7, E2F1, RRM1,
KIT, NP and EPOR. Many of these genes have been reported to be
deregulated in CLL, as we confirmed in our analyses that showed
overexpression of LEF1, NFATC1, NFATC2 and PAX5 in B
lymphocytes from CLL patients compared with B lymphocytes
from healthy controls (data not shown). PCR results confirmed the
microarray data in the analyzed genes such as GAS7, E2F1 and
FCRL2 (Figure S2).
Moreover, 13q-H CLL patients were also characterized by a
striking overrepresentation of deregulated miRNAs. A total of 15
miRNAs were deregulated in 13q-H relative to 13q-L patients.
Most of them (eleven) were downregulated while four were
upregulated in 13q-H CLL (Table 1).
Signaling Pathways and Functional Ontology Analyses of
Genes Differentially Expressed in 13q-H Patients
To determine the biological significance of the deregulated
genes, a further analysis of the 3 450 deregulated genes
characterizing the 13q-H CLL was carried out, revealing in this
group of patients the involvement of several pathways (Table 2).
These pathways are primarily related to cell proliferation,
apoptosis and cell signaling. Thus the BCR pathway was
upregulated in 13q-H CLL patients. In fact, 21 genes from this
pathway were overexpressed in 13q-H CLLs, some of which, such
as SYK, BLNK and PRKCB1, were previously related to CLL
pathogenesis (Figure S3). We also observed an imbalance in
proliferation and apoptosis in 13q-H patients, due to upregulation
of antiapoptotic genes (BCL2) and decreased expression of
proapoptotic genes (RASSF5, BAD, CASP8, CASP10, FAS) in 13q-
Figure 2. Quantitative RT-PCR validation for miR-15a, miR-29a, miR-155 and miR-223 in independent CLL patients. Relative
expression of miR-15a, miR-29a, miR-155 and miR-223 [represented as arbitrary units (a.u.)] was evaluated by individual TaqMan miRNA assays
performed in duplicate and normalized to RNU43 (22dCt). Box plots indicate the median value (horizontal line) and the 25th–75th percentile range
(box) while whiskers showing the maximum and minimum values. Values outside this range are shown as outliers (open circles). P-values were
determined by the Mann-Whitney U test. In every case, miRNAs downregulated in 13q-H CLL patients relative to 13q-L patients were also found to be
downregulated by quantitative RT-PCR. Similar observations were made for miR-155, which was upregulated in 13q-H patients. All comparisons were
statistically significant (P,0.05).
doi:10.1371/journal.pone.0048485.g002
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H patients. Moreover, our analysis showed an overexpression of
genes promoting proliferation, such as LEF1, E2F5 and RRAS2.
To ensure that the gene expression profiles accurately reflected the
upregulation of BCR signaling pathway and the deregulation of
apoptosis-related genes, representative genes that were differen-
tially expressed in 13q-H patients were assessed by semi-
quantitative SYBRgreen PCR analysis. These included SYK,
BLNK and PRKCB1 (BCR signaling pathway), BCL2 (apoptosis)
and LEF1 and RRAS2 (proliferation). The semi-quantitative PCR
results were in close agreement with the microarray data (Figure 1)
confirming the overexpression of these genes in 13q-H CLLs
compared with 13q-L. Western blot analysis should be made for a
more concluding validation after mRNA screening. Unfortunately,
due to the lack of material, this was not possible in this study.
miRNA Deregulation in 13q-H CLL Patients
The analysis of miRNA expression in 13q-H and 13q-L CLL
patients revealed that fifteen miRNAs were deregulated in 13q-H
CLL patients: hsa-miR-155 was the most highly upregulated
miRNA (Rfold = 3.70), while hsa-miR-223 was the most signifi-
cantly downregulated (Rfold = 0.10). Four of the deregulated
miRNAs (miR-15a, miR-29a, miR-155 and miR- 223) were
further assayed by quantitative RT-PCR for validation purposes in
24 CLL samples displaying 13q-. Results confirmed the upregula-
tion of miR-155 and the downregulation of miR-15a, miR-29a
and miR- 223 in 13q-H samples relative to 13q-L (Figure 2).
The influence of these deregulated miRNAs on 13q- patients
was assessed (Figure S2). Specifically, we investigated whether
observed changes in miRNAs were correlated with changes in the
expression of genes. Therefore the post-transcriptional regulatory
network of miRNA and genes in CLL patients with more than
80% of 13q- cells was carried out by analyzing the miRNA-
mRNA relationships. A total of 1 027 mRNA putative targets with
altered expression in 13q-H CLL patients were found (Table S4).
Indeed, because miRNAs tend to downregulate the target genes,
we focused our study on the subset of 11 miRNAs selected for
analysis in IPA and the 432 genes predicted to be regulated by
them and characterized by expression profiles stringly antic-
orrelated. Functional analysis revealed that transcription was the
cell function most strongly affected by these miRNAs, with a total
of 97 genes affected by the 11 selected miRNAs. Modification of
proteins (n = 41), proliferation of immune cells (n = 34), and
activation of protein binding sites (n = 32) were other important
functions affected by these miRNAs (Table S5). Finally we
performed a functional analysis of the 11 miRNAs and their 432
putative targets. The pathway analysis demonstrated that, again, B
Figure 3. Most significant cellular functions affected by the deregulation of miRNAs in 13q-H CLL patients. 432 out of the 1027
predicted mRNA target genes of the deregulated miRNAs in 13q-H CLL patients appeared also deregulated in our analysis. A functional enrichement
analysis was performed in this dataset. Category names are presented on the vertical axis. Of note, B cell receptor signaling and NF-kB signaling were
among the most significant cellular functions affected. The significance of the association between the dataset and the canonical pathway was
measured in two ways: (1) the ratio of the number of genes from the dataset that met the expression value cut-off that map onto the pathway
divided by the total number of molecules that exist in the canonical pathway, represented by grey squares in the graph and (2) the P-value
determining the probability of the association between the genes in the dataset and the canonical pathway, calculated by Fisher’s exact test. The
horizontal axis on the top indicates the 2log (P value) and the horizontal axis at the bottom, the ratio. In both cases, the higher value indicates the
higher significance.
doi:10.1371/journal.pone.0048485.g003
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cell receptor signaling, PI3K signaling and NFkB signaling were
among the most strongly affected pathways in 13q-H patients
(Figure 3), highlighting the importance of miRNA regulation in
CLL. MiR-155, the most overexpressed miRNA in 13q-H, was
negatively correlated with the expression of 90 of the 182 expected
genes (49%), demonstrating a relationship between miRNA and
gene deregulation. Interestingly, most of these putative targets
were assigned to the functional categories of transcription
regulation (P= 0.002). Moreover, we found several miRNAs
whose targets that were experimentally observed or predicted
with high confidence were strongly related to CLLs such as BCL2
(miR-15, miR-206, miR-106b and miR-34a), TCL1A (miR-29a)
and LEF1 (miR-34a) (Table 3).
The GEP of 13q-H CLL Patients is Similar to that in CLL
Patients with 11q or 17p Losses
We also analyzed the gene signature of CLL high risk
cytogenetic subgroups in comparison with 13q- patients. Surpris-
ingly, a significant number of deregulated genes were found to be
shared between the genes that differentiate 13q subgroups and
13q-L and high risk subgroup of patients. That is, the GEP of 13q-
H CLL patients resembled the gene expression pattern of patients
with 17p- or 11q- abnormalities (Figure 4A). In fact, both
subgroups of CLL patients (13q-H and the 17p- and 11q-
subgroup) shared 1 325 genes (46%) of the deregulated genes in
the global analysis including all CLL subtypes. By contrast, the
comparison between the GEP of 13q-H patients and those with
losses in either 17p or 11q showed fewer differences in expression
(Figure S4).
To evaluate the biological significance of the observed similarity
between the 13q-H and the 17p2/11q- signatures, we used the
Ingenuity Pathway Analysis comparative tool, which facilitates the
functional comparison of several panels of differentially expressed
genes. Thus, we identified several commonly deregulated biolog-
ical functions in both gene signatures (Figure 4B), such as cell
cycle, cell death, cellular growth and proliferation. Finally,
pathway analysis was performed on those genes commonly
upregulated or downregulated in 13q-H, 17p- and 11q- patients
in comparison with the 13q-L subgroup (Table S6). In accordance
with the comparative analysis results, several commonly deregu-
lated pathways of relevance in CLL pathogenesis were observed.
The most significant of these were the B cell receptor signaling
pathway for commonly upregulated genes, and the cell cycle
control of chromosomal replication pathway for commonly
downregulated genes in patients showing 13q-H, 17p- or 11q-
(Table S6). The expression of the TCL1 gene had one of the lowest
q-values (0.002) with higher expression levels in patients with 13q-
H, 17p- and 11q-. Of note, 13q-H, 17p- and 11q- patients also
shared the deregulation of several miRNAs (Table 1).
Genome-wide Expression Differentiates 13q-H CLLs from
13q-L CLLs and Controls
To validate the differences observed between the subgroups of
13q- CLL patients and get a visualization of these, we applied the
Principal Component Analysis (PCA) in an independent series of
patients. The clustering algorithm of PCA reduces complex
multidimensional data to a few specified dimensions so that it
can be visualized effectively. For a better characterization of the
Table 3. Most significant target genes affected by deregulation in miRNA in 13q-H CLL patients.
Target miRNA
Symbol Fold Change B-cells related pathways ID Fold Change
hsa-mir-206 0.708
hsa-mir-15a 0.492
BCL2 2.132 Apoptosis hsa-mir-106b 0.519
hsa-mir-204 0.569
hsa-mir-34a 0.687
hsa-mir-206 0.708
E2F5 2.624 DNA Damage Response hsa-mir-106b 0.519
hsa-mir-34a 0.687
FOS 0.447 B Cell Activating Factor,CD27 hsa-mir-155 3.701
LEF1 2.835 ILK, Wnt hsa-mir-34a 0.687
MAP2K6 3.558 BCR,CD27 hsa-mir-29a 0.510
MAP3K12 1.254 BCR,CD27 hsa-mir-106b 0.519
MAP3K14 1.348 Apoptosis,B Cell Activating Factor,BCR,CD27 hsa-mir-106b 0.519
MAP3K9 1.400 BCR,CD27 hsa-mir-106b 0.519
MYD88 0.752 NF-kB,Toll-like Receptor hsa-mir-155 3.701
PLCB1 0.773 PI3K hsa-mir-205 1.383
RRAS2 1.931 Apoptosis, BCR hsa-mir-223 0.102
hsa-mir-15a 0.492
SOS1 2.352 BCR hsa-mir-106b 0.519
hsa-mir-204 0.569
TCL1A 7.848 Akt hsa-mir-29a 0.510
doi:10.1371/journal.pone.0048485.t003
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differences, we included in this cohort patients with normal FISH
(nCLL) and healthy donors as two different types of controls.
Overall, the expression pattern of B lymphocytes from 13q-H
and 13q-L CLL patients and nCLLs was notably different from
the gene expression profile of B lymphocytes from healthy donors,
as expected (Figure 5). PCA revealed a cumulative variance
between groups of 48.3%, 60.9% and 68.3% corresponding to
one, two and three of the initial components, respectively. Since
the first three principal components explained a considerable
proportion of the overall variance (68%), the 3D representation
was able to show the main similarities and differences between
categories. Notably, the 13q-H samples were largely separated
from the others. Thus, 13q-H patients had a distinctive GEP that
was different not only from healthy donors but also from all other
CLLs, including 13q-L patients. By contrast, the gene expression
of B lymphocytes from 13q-L CLL and nCLL was similar
(Figure 5). SAM analysis revealed differences in the expression of
15 332 and 16 754 genes between CD19+cells from 13q-L or
nCLL compared with B lymphocytes from healthy donors,
respectively, while both subgroups (13q-L and nCLL patients)
shared the deregulation of 13 749 genes (data not shown).
Moreover, the analysis failed to demonstrate differences between
nCLL and 13q-L patients, while 131 genes were differentially
expressed in comparison with 13q-H (data not shown).
Thus, both qualitatively (PCA) and quantitative (SAM) analysis
showed that the gene expression profile of 13q- CLLs is different
depending on the percentage of cells displaying this aberration.
IgVH Mutational Status and Mono/biallelic 13q14
Deletion in 13q-patients
Given that the prognostic significance of IgVH mutations is
independent from that of cytogenetic abnormalities, we also
analyzed the IgVH mutational status in the 13q- subgroups. There
was no significant difference between both 13q- subgroups
(P= 0.664).
Regarding the distribution of biallelic 13q14 deletion in both
13q- subgroups, no correlation between the presence of biallelic
13q14 deletion and the percentage of 13q- cells was observed.
Thus in the group of patients with 3 of the 32 cases (9%) had a
biallelic loss of 13q, while in the group of 13q-L 5 of 38 patients
(13%) showed a biallelic loss on 13q. (P=N.S.).
Figure 4. Differential expression analysis followed by pathway analysis revealed commonly deregulated biological processes in
CLL patients with a high load of 13q- cells, 17p- and 11q-. A. Heatmap of 3450 differentially expressed genes in CLL patients with a
high number of losses in 13q (red), losses in 17p or 11q (magenta) and a low number of losses in 13q (blue). Differentially regulated
genes were identified using Significance Analysis of Microarray (SAM), with a false discovery rate 5%, followed by the Global Test algorithm to test the
candidate genes associated with the group of patients with a high number of losses. Individual patients are arranged in columns with the expression
level for each gene across rows. Normalized gene expression values are color-coded (standard deviation from mean): red and green indicate high and
low expression, respectively. All patients with 13q-L were clustered on the right side of the map in a homogeneous manner and separately from 13q-
H and 17p2/11q-, which clustered together, showing that the gene expression profile (GEP) of CLL cases with higher percentages of 13q- cells is
similar to that of 17p- and 11q-, while CLL patients with lower percentages of 13q- cells had a different gene profile. B. Commonly deregulated
biological functions in 13q-H and 17p2/11q- CLL patients compared with 13q-L CLL subgroup. Biological function names are presented
on the vertical axis and the number of deregulated genes involved in each function, in the horizontal one. Fisher’s exact test was used to examine the
probability of the association between the genes in the dataset and the functional category. The color-coded bar plot (dark grey, light grey and black
bars) depicts the analysis results. 13q-H patients showed marked differences in the expression of genes related to several cellular functions compared
with 13q-L CLL patients (comparison 1, dark grey bars). In addition, most of these cellular functions were also deregulated in comparison with high-
risk cytogenetic subgroups (17p- and 11q-) and 13q-L CLL patients (comparison 2, light grey bars). Thus, 13q-H, 17p- and 11q- patients share the
deregulation of several important functions relative to 13q-L patients. Furthermore, a small number of genes related to cell cycle, cell growth and
DNA repair (comparison 3, black bars) were found to be differentially expressed in the 13q-H group in a comparison of this subgroup of patients and
high-risk cytogenetic subgroups.
doi:10.1371/journal.pone.0048485.g004
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Discussion
13q deletion (13q-) is the most common cytogenetic aberration
in CLL and it is usually associated with the most favourable
prognosis as a sole abnormality [5]. However, recent studies have
shown that CLL patients carrying higher percentages of 13q- cells
have more aggressive clinical courses [11–13]. By combining gene
expression profile and miRNA analysis, we have shown that 13q-
patients are also a biologically heterogeneous group, in which a
higher number of 13q- cells (13q-H) could involve the deregulation
of relevant cellular pathways. Thus, several pathways are involved
in 13q-H patients (Table 2 and Table S3), BCR signaling, NFkB
signaling and antiapoptotic pathways being of special interest in
CLL. Deregulation of several miRNAs (Table 1) was also
observed. The influence of other factors with prognostic relevance
in CLL, such as IGVH mutational status, was discarded.
The BCR is an essential signal transduction pathway for the
survival and proliferation of mature B lymphocytes. In the present
study, monoclonal B-cells in 13q-H CLL patients exhibit a
molecular signature characterized by the overexpression of genes
mainly involved in BCR signaling (Figure 1). There is now strong
evidence that signaling via the B cell receptor plays a major role in
the development of CLL, and it could be related to the different
clinical outcomes of CLL [26]. Thus, the BCR pathway is
activated in poor prognosis CLL patients (IGHV unmutated), and
the overexpression of several molecules involved in this pathway
has been reported in advanced stages of the disease [27,28]. In
addition, SYK expression is enhanced in CLL relative to healthy B
cells and also in unmutated compared with mutated CLL, possibly
Figure 5. CLL patients with a high number of 13q- cells can be differenciated based on their expression profile. Principal component
analysis (PCA) plot of CD19+cells from healthy controls (green), CLL with normal FISH (sky blue), 13q-H CLL (red) and 13q-L CLL (dark blue) was carried
out using the 28,806 remaining genes after filtering the normalized gene expression matrices to remove the least variable genes (25%). Each sphere
represents a single GEP. The result of the PCA shows a cumulative variance of 48.3%, 60.9% and 68.3% corresponding to one, two or three of the
initial components, respectively. The expression pattern of CD19+cells from CLL patients is notably different from the gene expression profile of
CD19+cells from healthy donors. Of note, the PCA analysis shows that 13q-H CLL patients have a distinctive gene expression profile. By contrast, the
gene expression of B lymphocytes from 13q-L CLL and nCLL was similar.
doi:10.1371/journal.pone.0048485.g005
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reflecting the increased BCR signaling in these patients [29]. In
our study 13q-H CLL also overexpressed SYK (Figure 1), providing
new evidence of the involvement of the BCR pathway in this
group of CLLs. In addition, this group of patients also showed
upregulation of CD79b. Chronic active BCR signaling due to point
mutations in CD79b has recently been identified as a key
pathogenic mechanism in aggressive B-cell lymphoma, and results
in constitutive nuclear factor-kB (NF-kB) activation [30]. Interest-
ingly, CLL patients with deletions on 17p or 11q or those with
losses in 13q in a high percentage of cells had an increased
expression of a cluster of genes comprising several PKCs, such as
PRKCB1 and PRKCZ. Previous studies have shown an overex-
pression of PKC in human CLLs, which is part of a poor-prognosis
gene cluster in CLL linked to the transmission of BCR signals such
as calcineurin-NFAT and NF-kB, which our analysis also revealed
to be deregulated (Table 2) [31,32]. Furthermore, the overexpres-
sion of calcium metabolism-related genes as well as several MAPK
in 13q-H patients was also observed in the present study, which
would be consistent with these previous studies (Table 2).
One of the hallmarks of this clinically heterogeneous disease is
defective apoptosis, which is considered to contribute not only to
cell accumulation but also to disease progression and resistance to
therapy [26]. In this study we report the overexpression of genes
involved in promoting cell survival and antiapoptotic pathways, as
well as the downregulation of several proapoptotic genes in 13q-H
CLL patients (Table 2 and Table S3). We confirm the
overexpression of LEF-1 in CLL B cells compared with B cells
from healthy donors (data not shown), as previously reported [33],
but we also observed upregulation of LEF-1 and other genes
involved in the Wnt signaling pathway in 17p-, 11q- and 13q-H
patients in comparison with 13q-L cases. Wnt pathway gene
expression is widely known to be deregulated in CLL [34,35].
Alterations of RAS signaling are associated with potent oncogenic
effects, which keep the cell in a proliferative state and block
apoptosis, thereby paving the way for cancer formation. Overex-
pression of RRAS and other molecules involved in this signaling
cascade, such as SOS1, RHOC and several MAP kinases, was also
observed. In addition, apoptosis was also deregulated in 13q-H
patients by the involvement of both mitochondrial (BCL2 and
several caspases) and extrinsic (FAS) pathways. Interestingly, the
apoptotic signature of 13q-H patients showed a similar pattern of
deregulation to that of high-risk cytogenetic groups (Figure 4B),
since they both featured the alteration of several genes involved in
the classic apoptotic pathway (mitochondrial). Sustained BCR
signaling has also been reported to have an antiapoptotic effect
[36]. Thus, in 13q-H CLL patients, our study shows an imbalance
between the proliferative and apoptotic signals, which could
explain the higher level of lymphocytosis and the poor outcome
previously described in these patients [11].
An aberrant cellular miRNA expression profile in CLL cells has
already been described and the changes correlate well with
prognostic factors, including ZAP-70 expression status and IgVH
mutations in CLL patients [37]. A recent study evaluating
microRNAs as a signature for CLL patients with specific
chromosomal abnormalities found nine miRNAs whose expression
values were correlated with a specific karyotype [38]. In our study
we found that several miRNAs were deregulated in 13q-H patients
(Table 1), some of which had been previously reported in CLL
(Table 3). Several important miRNAs, such as miR223, miR-29a
and miR-181, were downregulated in 13q-H and high-risk
cytogenetic subgroups, which could be related to the worse
outcome in these groups of patients [39,40]. By contrast,
overexpression of miR-155 was observed, which could be related
to enhanced BCR-activation, as previously reported [41]. The
pathogenic role of deletion 13q in CLL has been related to the lack
of B-cell proliferation control allegedly determined by the deletion
of the DLEU2/MIR15A/MIR16-1 locus [42]. Interestingly, miR-
15a was downregulated in 13q-H CLL patients and it has been
reported to induce apoptosis through the negative regulation of
BCL2, overexpressed in the 13q-H group of patients. It should be
noted that a third of deregulated genes in 13q-H compared with
13q-L were putative targets of miRNAs also altered in this
analysis, supporting the presence of a specific relationship between
miRNA and gene expression in 13q-H CLL patients. Most of
these genes were related to TGF or BCR signaling and confirmed
these pathways to be those most commonly affected by miRNA
deregulation in 13q-H patients. Among the putative target
mRNAs we found many genes, such as TCL1A, BCL2, LEF1
[33,43,44], to be closely involved in CLLs (Table 3). These results
suggest that miRNAs have a key role in the reported heterogeneity
of 13q- patients. Surprisingly, our results suggest that some of the
biological characteristics of 13q-H CLL patients are similar to
those of high-risk cytogenetic subgroups, since they share the
deregulation of several key signaling pathways (Figure 4B; Table
S6). However, 13q-L patients had similar gene expression to that
of CLL with normal FISH (Figure 5).
Therefore, this study provides new evidence regarding the
heterogeneity of 13q deletion in CLL patients, showing that
apoptosis, BCR and NF-kB signaling as well as miRNA regulation
are the most significant affected pathways in 13q-H CLL patients.
The identification of the mechanisms responsible for the clinical
heterogeneity of CLL, including the mutations recently described
[45,46] and the critical signaling pathways affected can lead to a
better understanding of the molecular pathogenesis of the disease.
Supporting Information
Figure S1 Summary of the miRNA analysis performed
in the study. The chart explains the steps involved in the
identification and validation of the miRNAs and their deregulated
targets in 13q- CLL patients.
(TIF)
Figure S2 Box plot of the expression levels of three
genes with significant differences between 13q-H and
13q-L patients, assessed by semi-quantitative PCR. Box
plots show the values for GAS7, E2F1 and FCRL2 relative
expression [represented as arbitrary units (a.u.)], showing a
significant difference in the level of expression between 13q-H
and 13q-L CLL patients. The thick line inside the box plot
indicates median expression levels, the limits of the box represent
the 25th and 75th percentiles, and the whiskers show the
maximum and minimum values. Outliers (extreme values falling
outside the main distribution) are represented by open circles.
Statistical significance was determined using the Mann-Whitney U
test (P,0.05).
(TIF)
Figure S3 BCR signaling pathway identified as the top
canonical pathway altered in CLL patients with higher
percentages of 13q- losses according to the Ingenuity
Pathway Analysis knowledge base. Genes significantly
differentially expressed between CLL with 80% or more of cells
with loss of 13q (13q-H) and CLL with losses in 13q in fewer than
80% of cells (13q-L) were mapped to the pathway and colored in
red if the expression levels were higher, or in green if they were
lower in 13q-H than in 13q-L cases. Significant positions of the
pathway are occupied by genes deregulated in our analysis,
indicating that this pathway is affected in 13q-H patients. CLL
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patients with 17p and 11q deletions showed similar deregulation in
this pathway.
(TIF)
Figure S4 Overlap of differentially expressed genes as
analyzed by SAM. Venn diagram illustrating the number of
significantly affected genes in common and distinct for the
contrasts (1) and (2). 13q-H and 17p2/11q- shared the
deregulation of 46% of genes (n = 1325) relative to 13q-L.
(TIF)
Table S1 Clinical and biological features of CLL patients
included in the study.
(XLS)
Table S2 Sequences of primers used for SYBR Green detection.
(XLS)
Table S3 Enriched functional annotations terms associated with
the 3450 differentially expressed genes in 13q-H CLL patients.
Genes were clustered into functional categories using the DAVID
Bioinformatics Database Gene Functional Classification Tool
(NIAID/NIH). The P-value is provided by DAVID bioinformatics
resources.
(XLS)
Table S4 miRNAs and their predicted targets (n = 1027) that are
significantly deregulated in 13q-H CLL patients. By applying an
integrated miRNA-mRNA analysis, mRNA targets were identified
for the list of miRNAs deregulated in 13q-H CLL patients. The P-
value for each predicted target gene refers to the contrast between
13q-H and 13q-L CLL patients.
(XLS)
Table S5 Functional analysis of the potential target genes of the
deregulated miRNAs in CLL patients with a high number of 13q-
cells (13q-H). The 432 mRNA target genes that showed an inverse
relationship with miRNA expression level were input into
Ingenuity (Ingenuity Systems, Inc.) and core analysis was then
performed to retrieve the target genes’ association with biological
functions of relevance in CLL.
(XLS)
Table S6 Most significant differentially expressed genes in
patients with 80% or more cells showing 13q- (13q-H) and 17p/
11q deletion compared with 13q-L patients. (Upper: overex-
pressed; Lower: underexpressed in 13q-H, 17p- and 11q- patients
with respect to the 13q-L CLL patients).
(XLS)
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